Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | How will EIK1003 fit in the treatment landscape of prostate cancer?

Guru Sonpavde • 24 Oct 2026
ESMO 2026
Genitourinary Cancer Prostate Cancer EIK1003

Guru Sonpavde, MD, AdventHealth Cancer Institute, Orlando, FL, comments on the potential applications of EIK1003, a PARP1-selective inhibitor in prostate cancer, suggesting it could be effective in both hormone-sensitive and hormone-insensitive spaces, as well as in earlier disease stages. The drug may remain active even after patients have failed or progressed on non-specific part inhibitors, due to its potentially better potency and therapeutic index. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Guru Sonpavde

Assessing the safety and efficacy of EIK1003, a novel selective PARP1 inhibitior
0:39
Assessing the safety and efficacy of EIK1003, a novel selective PARP1 inhibitior
Guru Sonpavde • 24 Oct 2026
EIK1003-001: EIK1003 plus abiraterone in metastatic prostate cancer
1:20
EIK1003-001: EIK1003 plus abiraterone in metastatic prostate cancer
Guru Sonpavde • 24 Oct 2026
KEYNOTE-905/EV-303: perioperative EV and pembrolizumab in MIBC
2:33
KEYNOTE-905/EV-303: perioperative EV and pembrolizumab in MIBC
Guru Sonpavde • 19 Oct 2025
Dose-optimization of LY3866288 for FGFR3-mutated solid tumors in FORAGER-1
1:49
Dose-optimization of LY3866288 for FGFR3-mutated solid tumors in FORAGER-1
Guru Sonpavde • 19 Oct 2025

Related Videos

Real-world outcomes highlight unmet needs in R/R germ cell tumors
1:26
Real-world outcomes highlight unmet needs in R/R germ cell tumors
Darren Feldman • 24 Oct 2026
The future of targeting claudin-6 in relapsed germ cell tumors
0:52
The future of targeting claudin-6 in relapsed germ cell tumors
Darren Feldman • 24 Oct 2026
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
2:18
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
Darren Feldman • 24 Oct 2026
Assessing the safety and efficacy of EIK1003, a novel selective PARP1 inhibitior
0:39
Assessing the safety and efficacy of EIK1003, a novel selective PARP1 inhibitior
Guru Sonpavde • 24 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals